Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial.

Weekly patient-reported outcome symptom monitoring increased median overall survival by 5 months in lung cancer patients across stages I-IV in a real-world setting.

• Why it matters: Improving long-term survival in lung cancer is critical, yet evidence on symptom monitoring's impact outside resource-intensive studies is limited, especially over extended follow-up periods.
• What they did: A multicentre, stepped-wedged, cluster-randomised trial involving 515 patients assessed the effect of weekly online symptom assessments over one year, with long-term survival outcomes analyzed up to 5 years.
• The result: PRO symptom monitoring was associated with a significant survival benefit, extending median overall survival from 21 to 26 months, highlighting its potential to enhance routine lung cancer care.